Result of General Meeting relating to the proposed major transaction with Novartis

GlaxoSmithKline plc (GSK) announces that at its General Meeting held earlier today, the sole resolution was passed by shareholders by an overwhelming majority. As previously announced, the transaction is expected to complete during the first half of 2015, subject to approvals.

GlaxoSmithKline General Meeting Poll Results

The following table shows the votes cast in respect of the resolution:

<table>
<thead>
<tr>
<th>Resolution</th>
<th>Total votes for</th>
<th>%</th>
<th>Total votes against</th>
<th>%</th>
<th>Total votes cast</th>
<th>Votes withheld</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proposed major transaction with Novartis AG</td>
<td>3,606,194,474</td>
<td>99.79</td>
<td>7,672,471</td>
<td>0.21</td>
<td>3,613,866,945</td>
<td>11,617,644</td>
</tr>
</tbody>
</table>

In accordance with Listing Rule 9.6.2, a copy of the resolution will be submitted to the UK Listing Authority and will in due course be available for inspection at www.morningstar.co.uk/uk/NSM.

Notes:
* Includes discretionary votes.
** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

The following table provides further relevant information:

<table>
<thead>
<tr>
<th>Issued share capital (excluding Treasury Shares)</th>
<th>4,863,747,114</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)</td>
<td>74.54</td>
</tr>
<tr>
<td>Total shareholder population</td>
<td>139,567</td>
</tr>
<tr>
<td>Total number of proxies lodged</td>
<td>12,457</td>
</tr>
<tr>
<td>% of shareholders who lodged proxies</td>
<td>8.93</td>
</tr>
<tr>
<td>Number of shareholders, corporate representatives and proxies who attended the General Meeting</td>
<td>75</td>
</tr>
</tbody>
</table>

V A Whyte
Company Secretary
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit [www.gsk.com](http://www.gsk.com).

GSK enquiries:

**UK Media enquiries:**
- David Mawdsley +44 (0) 20 8047 5502 (London)
- Simon Steel +44 (0) 20 8047 5502 (London)
- Sarah Spencer + 44 (0) 20 8047 5502 (London)

**US Media enquiries:**
- Stephen Rea +1 215 751 4394 (Philadelphia)
- Sarah Alspach +1 202 715 1048 (Washington)
- Mary Anne Rhyne +1 919 483 0492 (North Carolina)

**Analyst/Investor enquiries:**
- Ziba Shamsi +44 (0) 20 8047 3289 (London)
- Tom Curry + 1 215 751 5419 (Philadelphia)
- Gary Davies +44 (0) 20 8047 5503 (London)
- James Dodwell +44 (0) 20 8047 2406 (London)
- Jeff McLaughlin +1 215 751 7002 (Philadelphia)

Information regarding forward-looking statements

This announcement includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “plans”, “projects”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and include, but are not limited to, statements regarding GSK’s intentions, beliefs or current expectations concerning, among other things, GSK’s business, results of operations, financial position, prospects, growth, strategies and the industry in which it operates as well as those of the Novartis businesses that are the subject of the transaction. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward-looking statements are not guarantees of future performance and the actual results of GSK’s operations and financial position, and the development of the markets and the industry in which GSK operates, may differ materially from those described in, or suggested by, the forward-looking statements contained in this announcement. The same applies in respect of the Novartis Businesses that are the subject of the transaction. In addition, even if the results of operations, financial position and the development of the markets and the industry in which GSK operates are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments to differ materially from those expressed or implied by the forward-looking statements including, without limitation, general economic and business conditions, industry trends, competition, changes in regulation, currency fluctuations, changes in its business strategy, political and economic uncertainty and other factors discussed in this announcement.

Forward-looking statements may, and often do, differ materially from actual results. Any forward-looking statements in this announcement speak only as of their respective dates, reflect GSK’s current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to GSK’s operations, results of operations and growth strategy. You should specifically consider the factors identified in this document, in addition to the risk factors that may affect GSK’s operations which are described under “Risk Factors” in the Company’s 2013 Annual Report on Form 20-F, which could cause actual results to differ before making any decision in relation to the Transaction as well as those of the Novartis businesses that are the subject of the transaction. Subject to the requirements of the FCA, the London Stock Exchange, the Listing Rules and the Disclosure and Transparency Rules (and/or any regulatory requirements) or applicable law, GSK explicitly disclaims any obligation or undertaking publicly to release the result of any revisions to any forward-looking statements in this announcement that may occur due to any change in GSK’s expectations or to reflect events or circumstances after the date of this announcement.